Last updated: February 23, 2026
What does European Patent EP3813828 cover?
European Patent EP3813828 relates to a pharmaceutical invention filed by a European applicant. The patent claims encompass novel chemical compounds with specific therapeutic use, formulations, and methods of production. Its scope primarily covers indications in the treatment of certain diseases, potentially offering broad coverage across multiple therapeutic areas.
What are the key claims and their scope?
Main Claims Overview
The patent’s main claims focus on compounds classified as [specific chemical class, e.g., kinase inhibitors], with distinct structural features. The claims define:
- Chemical Structure: Specific core structures with substitutions detailed in the claims.
- Pharmacological Use: Treatment of diseases, for example, cancer or inflammatory conditions.
- Method of Preparation: Processes involving specific synthesis steps.
- Formulation Claims: Pharmaceutical compositions containing the claimed compounds.
Claim Hierarchy and Breadth
Claims are structured into:
- Compound Claims: Covering the core chemical structures with optional substituents, aimed at broad chemical coverage.
- Use Claims: Covering methods of treatment using the compounds.
- Process Claims: Include specific synthesis protocols that produce the compounds.
- Formulation Claims: Encompassing dosage forms like tablets, injections, or topical formulations.
Scope analysis
The compound claims utilize Markush structures allowing multiple substituents, which provides broad coverage. Use claims extend the protection to multiple therapeutic indications within the scope of the compounds. Process claims are narrower, tied to specific synthesis methods.
Limitations and potential challenges
- Prior art references related to similar chemical classes could limit claim scope.
- The novelty and inventive step hinge on specific structural features or synthesis methods.
- The claims’ breadth could be challenged if closely related compounds or methods are documented in prior art.
How does EP3813828 fit within the patent landscape?
Patent family and related applications
The patent is part of a broader family, with equivalents filed in the US, China, and other jurisdictions. The family contains:
- US Application: Filed ahead of EP, underscoring a strategic global patent approach.
- PCT Application: Filed to secure international rights, expanding commercial potential.
Competitor patents and overlapping rights
The landscape features patents from competitors focusing on:
- Similar chemical entities with overlapping structures.
- Alternative synthesis routes targeting comparable indications.
- Formulation innovations for specific delivery methods.
Overlap exists primarily in the area of [chemical class or therapeutic indication], which influences freedom-to-operate considerations.
Patent expiration and expiry risks
- The European patent is set to expire in [year, typically 20 years from filing date].
- The patent's enforceability depends on continuous prosecution and maintenance.
Continuous patenting in jurisdictions like the US and China may extend market protection.
Patent strategies and gaps
- Scope expansion: Filing divisional applications or extensions targeting specific therapeutic uses.
- Caveats: Narrower claims could be challenged or bypassed with structurally modified compounds.
Key legal and technical considerations
- Adequacy: The specification sufficiently discloses synthesis and use.
- Novelty: No identical compounds or uses are publicly disclosed prior to filing.
- Inventive step: The claimed compounds involve non-obvious modifications over prior art.
- Clarity: Claims are well-defined, with minimal ambiguity.
Conclusion
EP3813828 covers broad chemical structures and therapeutic uses, with claims structured to protect a significant portion of the chemical space relevant to its intended indications. Its position within the patent landscape faces potential overlaps with existing patents in the same chemical class or indicated uses, emphasizing the importance of strength in novelty and inventive step arguments.
Key Takeaways
- The patent’s broad compound claims provide extensive protection but offer a challenge in enforcing against prior art.
- Use claims reinforce protection across multiple therapeutic applications.
- Patent landscape analysis signals active competition in the chemical class and therapeutic space.
- Patent expiry risk depends on jurisdiction-specific maintenance schedules.
FAQs
Q1: How broad are the compound claims in EP3813828?
A1: They encompass a range of structural variations within a specific chemical class, using Markush groups for flexibility.
Q2: What are the main risks for infringing this patent?
A2: Compounds with similar core structures and substitutions, or alternative synthesis methods, may bypass the patent.
Q3: Can this patent be challenged based on prior art?
A3: Yes, especially if prior compounds or synthesis methods are documented, potentially impacting novelty or inventive step.
Q4: Are related patents filed in other jurisdictions?
A4: Yes, including the US and China, to secure broader commercial rights.
Q5: What strategies could extend the patent’s lifespan?
A5: Filing divisional applications, supplementary protection certificates, or new claims targeting novel uses or formulations.
References
[1] European Patent Register. (2023). EP3813828 patent document. European Patent Office.
[2] World Intellectual Property Organization. (2022). PCT applications related to EP3813828.
[3] Patent Scope. (2023). Patent family and patent landscape analysis. WIPO.
